A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy

References

• Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, Jacobs M, Ryffel B, Quesniaux VF. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007; 179:1178 - 89; PMID: 17617611
   PubMed Web of Science ®Google Scholar
• Graves DT, Chen CP, Douville C, Jiang Y. Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection. Infect Immun 2000; 68:4746 - 51; http://dx.doi.org/10.1128/IAI.68.8.4746-4751.2000; PMID: 10899881
   PubMed Web of Science ®Google Scholar
• Hise AG, Tomalka J, Ganesan S, Patel K, Hall BA, Brown GD, Fitzgerald KA. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009; 5:487 - 97; http://dx.doi.org/10.1016/j.chom.2009.05.002; PMID: 19454352
   PubMed Web of Science ®Google Scholar
• Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006; 193:1419 - 26; http://dx.doi.org/10.1086/503363; PMID: 16619190
   PubMed Web of Science ®Google Scholar
• Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, Mortellaro A. The rhapsody of NLRPs: master players of inflammation...and a lot more. Immunol Res 2012; 53:78 - 90; http://dx.doi.org/10.1007/s12026-012-8272-z; PMID: 22427013
   PubMed Web of Science ®Google Scholar
• Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011; 4:39 - 49; http://dx.doi.org/10.2147/JIR.S11330; PMID: 22096368
   PubMedGoogle Scholar
• Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010; 11:897 - 904; http://dx.doi.org/10.1038/ni.1935; PMID: 20835230
   PubMed Web of Science ®Google Scholar
• Conforti-Andreoni C, Ricciardi-Castagnoli P, Mortellaro A. The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cell Mol Immunol 2011; 8:135 - 45; http://dx.doi.org/10.1038/cmi.2010.81; PMID: 21258359
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4:378 - 85; http://dx.doi.org/10.1016/j.coph.2004.03.010; PMID: 15251132
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201:1355 - 9; http://dx.doi.org/10.1084/jem.20050640; PMID: 15867089
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010; 21:157 - 63; http://dx.doi.org/10.1016/j.ejim.2010.03.005; PMID: 20493414
   PubMed Web of Science ®Google Scholar
• Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, Bohmann DJ, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 2010; 285:20607 - 14; http://dx.doi.org/10.1074/jbc.M110.115790; PMID: 20410301
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9:47 - 52; http://dx.doi.org/10.1038/nm811; PMID: 12483208
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, et al, National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26 - 35; http://dx.doi.org/10.1002/art.23176; PMID: 18163497
   PubMed Web of Science ®Google Scholar
• Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin North Am 2005; 52:413 - 42, vi; http://dx.doi.org/10.1016/j.pcl.2005.01.007; PMID: 15820374
   PubMed Web of Science ®Google Scholar
• Solau-Gervais E, Robin C, Gambert C, Troller S, Danner S, Gombert B, Debiais F, Hankard R. Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine 2010; 77:47 - 9; http://dx.doi.org/10.1016/j.jbspin.2009.11.002; PMID: 20034832
   PubMed Web of Science ®Google Scholar
• CDC National Diabetes Fact Sheet. . General information and national estimates on diabetes in the US. 2007; 2008
   Google Scholar
• Moreland NJ, Susanto P, Lim E, Tay MY, Rajamanonmani R, Hanson BJ, Vasudevan SG. Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries. Int J Mol Sci 2012; 13:2618 - 35; http://dx.doi.org/10.3390/ijms13032618; PMID: 22489114
   PubMed Web of Science ®Google Scholar
• Graves BJ, Hatada MH, Hendrickson WA, Miller JK, Madison VS, Satow Y. Structure of interleukin 1 alpha at 2.7-A resolution. Biochemistry 1990; 29:2679 - 84; http://dx.doi.org/10.1021/bi00463a009; PMID: 2346741
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Wiesmann C, Sidhu SS. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A 2004; 101:12467 - 72; http://dx.doi.org/10.1073/pnas.0401786101; PMID: 15306681
   PubMed Web of Science ®Google Scholar
• Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol 1991; 217:133 - 51; http://dx.doi.org/10.1016/0022-2836(91)90617-F; PMID: 1988675
   PubMed Web of Science ®Google Scholar
• Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 2013; 425:94 - 111; http://dx.doi.org/10.1016/j.jmb.2012.09.021; PMID: 23041424
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28; http://dx.doi.org/10.1186/ar2143; PMID: 17352828
   PubMed Web of Science ®Google Scholar
• Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999; 13:1117 - 25; http://dx.doi.org/10.1016/S0889-8588(05)70115-5; PMID: 10626139
   PubMed Web of Science ®Google Scholar
• Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Lust JA. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006; 26:83 - 95; http://dx.doi.org/10.1089/jir.2006.26.83; PMID: 16487028
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1beta-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84:114 - 22; http://dx.doi.org/10.4065/84.2.114; PMID: 19181644
   PubMed Web of Science ®Google Scholar
• Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene 1996; 169:147 - 55; http://dx.doi.org/10.1016/0378-1119(95)00821-7; PMID: 8647439
   PubMed Web of Science ®Google Scholar
• Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996; 263:551 - 67; http://dx.doi.org/10.1006/jmbi.1996.0598; PMID: 8918938
   PubMed Web of Science ®Google Scholar
• Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.] Methods Mol Biol 2009; 525:353 - 76, xiii; http://dx.doi.org/10.1007/978-1-59745-554-1_19; PMID: 19252851
   PubMedGoogle Scholar
• Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293:865 - 81; http://dx.doi.org/10.1006/jmbi.1999.3192; PMID: 10543973
   PubMed Web of Science ®Google Scholar
• Novotny J, Bruccoleri RE, Saul FA. On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. Biochemistry 1989; 28:4735 - 49; http://dx.doi.org/10.1021/bi00437a034; PMID: 2475171
   PubMed Web of Science ®Google Scholar
• Kuroda D, Shirai H, Jacobson MP, Nakamura H. Computer-aided antibody design. Protein Eng Des Sel 2012; 25:507 - 21; http://dx.doi.org/10.1093/protein/gzs024; PMID: 22661385
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 2000; 1:253 - 63; http://dx.doi.org/10.2174/1389201003378906; PMID: 11469383
   PubMedGoogle Scholar
• Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388 - 400; http://dx.doi.org/10.1016/j.immuni.2012.01.018; PMID: 22444631
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Targeting the pathogenic role of interleukin 1beta in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 2009; 84:105 - 7; http://dx.doi.org/10.4065/84.2.105; PMID: 19181642
   PubMed Web of Science ®Google Scholar
• Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13:R54; http://dx.doi.org/10.1186/bcr2888; PMID: 21600050
   PubMedGoogle Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362 - 71; PMID: 16785532
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762 - 9; http://dx.doi.org/10.4049/jimmunol.1000303; PMID: 21296976
   PubMed Web of Science ®Google Scholar
• de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274:18218 - 30; http://dx.doi.org/10.1074/jbc.274.26.18218; PMID: 10373423
   PubMed Web of Science ®Google Scholar
• Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30:E9; http://dx.doi.org/10.1093/nar/30.2.e9; PMID: 11788735
   PubMed Web of Science ®Google Scholar
• Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007; 2:1269 - 75; http://dx.doi.org/10.1038/nprot.2007.173; PMID: 17546023
   PubMed Web of Science ®Google Scholar